Image Description

INVESTORS
& MEDIA

circle

PRESS RELEASES

  • Webcast Image Webcast
    X Q2 2018 Cytokinetics, Inc. Earnings Conference Call
    Jul 26, 2018 4:30 PM EDT

    Q2 2018 Cytokinetics, Inc. Earnings Conference Call
    Jul 26, 2018 4:30 PM EDT
Date Title and Summary
Toggle Summary Cytokinetics, Inc. Reports Second Quarter 2018 Financial Results
Phase 2 Study of Reldesemtiv in Patients with SMA  Showed Potentially Clinically Meaningful Effects  on Six Minute Walk Distance and Maximal Expiratory Pressure Results from Phase 2 Clinical Trial of Reldesemtiv in Patients with COPD Expected in Q3 Finalizing Preparations to Initiate Second Phase 3
Toggle Summary Cytokinetics to Announce Second Quarter Results on July 26, 2018
SOUTH SAN FRANCISCO, Calif. , July 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on July 26, 2018 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy Presented at the 2018 Annual Cure SMA Conference
First Study of Muscle-Directed Therapy in Patients with SMA Showed Potentially Clinically Meaningful Effects on Six Minute Walk Distance and Maximal Expiratory Pressure SOUTH SAN FRANCISCO, Calif. , June 16, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced data from
Toggle Summary Cytokinetics to Present at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif. , June 13, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at
Toggle Summary Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to be Presented at the 2018 Annual Cure SMA Conference on June 16, 2018
SOUTH SAN FRANCISCO, Calif. , June 08, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented in an oral presentation at the 2018 Annual Cure SMA
Toggle Summary Cytokinetics and Cure SMA Renew and Expand Partnership to Advance Education and Awareness of SMA
ELK GROVE VILLAGE, Ill. and SOUTH SAN FRANCISCO, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Cure SMA and Cytokinetics today announced an expanded partnership to increase education, awareness and fundraising for spinal muscular atrophy (SMA).  As a National Platinum Partner for 2018, Cytokinetics will
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 16, 2018 at 10:30 AM Pacific Time at the Embassy Suites Hotel , located at 250 Gateway Boulevard in South
Toggle Summary Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif. and WASHINGTON, May 01, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is renewing its Gold Level Sponsorship of the National Walks to
Toggle Summary Cytokinetics, Inc. Reports First Quarter 2018 Financial Results
Completed Enrollment in Phase 2 Study of Reldesemtiv in Patients with SMA; Data Expected in Q2 2018 Preparing to Initiate Second Phase 3 Clinical Trial of Omecamtiv Mecarbil SOUTH SAN FRANCISCO, Calif. , April 26, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) reported financial
Toggle Summary Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference
SOUTH SAN FRANCISCO, Calif. , April 24, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented by John Day , M.D., Ph.D., Professor of Neurology and
Toggle Summary Cytokinetics to Announce First Quarter Results on April 26, 2018
SOUTH SAN FRANCISCO, Calif. , April 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report first quarter results on April 26, 2018 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics to Present at March Investor Conferences
SOUTH SAN FRANCISCO, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: Cowen and Company 38 th
Toggle Summary Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq:CYTK) today announced that it is joining the global initiative to raise awareness of Rare Disease Day®, an international campaign led by the European Organisation for Rare Diseases (EURORDIS) and the
Toggle Summary Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results
  Company Provides 2018 Financial Guidance and Expected Milestones;  Reduced Operating Expenses vs. 2017; Over Two Years of Cash Based on Current Burn Rate CK-2127107 Advancing in Four Clinical Trials Under Collaboration with Astellas; Results Expected in 2018 with Data from Phase 2 Clinical Trial
Toggle Summary Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the RBC Capital Markets Global Healthcare Conference on Thursday, February 22,
Toggle Summary Cytokinetics Names Robert Califf, M.D., to Board of Directors
Appointment Strengthens Regulatory, Global Clinical Research and Cardiology Expertise as Company Advances Its Development Pipeline and Executes Against Its Vision 2020 SOUTH SAN FRANCISCO, Calif. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq:CYTK) today announced that
Toggle Summary Cytokinetics to Announce Fourth Quarter Results on February 15, 2018
SOUTH SAN FRANCISCO, Calif. , Feb. 02, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report fourth quarter results on February 15, 2018 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Progress Against Vision 2020
Multiple Clinical Trials Advance Under Collaborations with Astellas and Amgen Results from Four Clinical Trials of CK-2127107 Expected in 2018 Pipeline Expands with Three New Programs Advancing from Muscle Biology Research to Development SOUTH SAN FRANCISCO, Calif. , Jan.